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utilities were compared to the patient-derived utilities. Treatment
data, disease transition probabilities, and hepatitis C related
costs were obtained from published literature. The costs of
hepatitis C treatments were obtained from an Internet pharmacy.
All costs were adjusted to 2004 USD. RESULTS: When patient-
reported utilities were used for HCV genotype 1, peginterferon
gained 1.28 additional quality-adjusted life years (QALYs) com-
pared with no treatment. The QALYs ranged from 0.71 to 2.35
when expert panel-estimated utilities were employed. For HCV
genotype 2 or 3 patients, peginterferon group had 2.72 more
QALYs than no treatment using patient-reported utilities. When
expert panel utilities were used for genotype 2 or 3, peginter-
feron had 1.61 to 4.85 additional QALYs than no treatment.
Using patient-derived utilities, the expected costs per QALY for
HCV genotype 1 receiving peginterferon and interferon treat-
ment were $2439 and $2335, respectively. For genotype 2 or 3,
these costs were $1152 and $1085 per QALY, respectively. The
lifetime HCV related cost for patients received no treatment was
$1975 per QALY regardless of HCV genotype. CONCLUSION:
Many expert panel-estimated utilities provided higher estimates
of the beneﬁts, and thus lower cost per QALY, for HCV treat-
ments as compared to patient-reported utilities.
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For patients with chronic hepatitis B, emergence of lamivudine
resistance is associated with poor clinical outcomes, more rapid
disease progression and poor quality of life. The clinical impli-
cations of lamivudune resistance are well described but the
health care costs are not. OBJECTIVE: The objective of this
study was to evaluate the health care utilization and direct
medical cost within the ﬁrst year of developing a lamivudine
refractory infection in chronic hepatitis B (CHB) patients.
METHODS: Physician estimates of health care utilization for the
care of lamivudine refractory CHB patients were collected in 
a survey of physicians treating CHB patients in the US. A 
questionnaire was mailed to 165 physicians of which 51
responded. Data on health care utilization was computed for
each health care cost category (Physician visits, hospitalizations,
diagnostic tests and radiological examinations). Unit costs were
derived based on the Medicare Physician Fee Schedule for pro-
cedures, the 2002 Health Care Cost and Utilization Project data-
base for inpatient hospitalization costs, and average wholesale
prices for medication costs. RESULTS: The total non-drug, direct
medical cost within the ﬁrst year of developing a lamivudine
refractory infection in a CHB patient was estimated at $2925.
Among the different cost categories diagnostic tests and special-
ist visits were the major cost drivers, accounting for an estimated
45% and 41% of the overall cost, respectively. Seventy four
percent of the patients were estimated to require a specialist visit.
Only 2% of patients were estimated to require a hospitalization
accounting for a negligible proportion of the costs. CONCLU-
SION: The estimated non-drug costs for patients refractory to
lamivudine represent a substantial economic burden. In addition,
the additional costs of rescue therapy further increase the cost
impact and make it considerably higher than the annual direct
medical cost for CHB patients who do not develop viral 
resistance.
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OBJECTIVES: To analyse the utilisation of antibiotics within the
Slovak Republic between 1992 and 2003. Adherence to princi-
ples of antibiotic policy lead to fundamental short and long term
ﬁnancial savings within health care systems. METHODS: For
1992–2003, the data of systemic antibiotic use for ambulatory
care, aggregated at the level of the active substance, were col-
lected, in accordance with the Anatomic Therapeutic Chemical
(ATC) classiﬁcation and Deﬁned Daily Dose (DDD) measure-
ment unit (WHO). Data of wholesalers, who are legally obliged
provide this information to the Slovak Institute for Drug
Control, was used for this detailed analysis of the Slovak con-
sumption of antibiotics. RESULTS: Long term analysis shows
that the antibiotic consumption had been increasing in human
medicine within Slovakia. In 1992 the consumption of antibi-
otics at the level of 19.4 DDD/1000/day increased to 28.0
DDD/1000/day in 1999. This analysis focused on the situation
in antibiotic consumption in 2001 and 2003 in more detail. The
results show that in 2003 as opposed to 2001, the consumption
of antibiotics decreased by 900,000 packages. In ﬁnancial ﬁgures
can be noticed a increase by 1.75 €mill., because the average
price for one package of antibiotics was at the level of 4.84€ in
2001 but in 2003 the price increased to a level of 5.64€. From
our analysis a signiﬁcant increase in the ATB consumption
expressed by DDD/1000/day can be seen (In 2001 it was 25.78
but in 2003 we can see the consumption 26.95 DDD/1000/day).
CONCLUSIONS: Inseparable components of the Slovak antibi-
otic policy must be viewed realistically with regard to the 
consumption of antibiotics and resistance. Antibiotic resistance
is a major public health problem, and antibiotic use is 
increasingly recognised as the major selective pressure driving
this resistance.
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OBJECTIVES: Several studies show that in developing countries,
low–income patients use low price counterfeit drugs provided by
the illegal drug market. In Cameroon, those false drugs repre-
sent 40% of the street market and lead to malaria therapeutic
failure and inappropriate medical expenses. The Yaoundé
program aims to improve access to efﬁcient antimalarial drugs
by providing a differentiated price policy through the ofﬁcial
private pharmacy distribution sector,allowing access to efﬁcient
antimalarials to low–income population which would otherwise
use street market drugs. METHODS: In 31 retail pharmacies of
Yaoundé, artesunate (Arsumax®)was made available at a “no
proﬁt no loss” public price of 1170FCFA (1.78€) instead of
3400FCFA (5.8€), ie: -66%. Eligibility of patients was based on
income below the poverty level (established by the Ministry of
Economy as 30€ monthly households incomes per number of
dependences).Program effectiveness was assessed by evaluating
the number of new patients having access to this lower price
Arsumax®. RESULTS: After 6 months of implementation,
